• About Us
    • TWi USA
    • USA Team
  • Our Products
  • For Customers
    • Authorized Distributors
    • TWi USA State Licenses
    • Return Goods Policy
    • Customer Service Contacts
  • For Patients
    • Adverse Event Reporting, Product Complaints & Medical Information(FOr USA Only)
    • Sorafenib Co-Pay Savings Program
  • Contact Us

buPROPion Hydrochloride Extended-Release Tablets (XL)

Cyclobenzaprine Hydrochloride Extended-Release Capsules

Diltiazem Hydrochloride Extended-Release Capsules

Dimethyl Fumarate Delayed-Release Capsules

Donepezil tablets

Fenofibric Acid Delayed-Release Capsules

Fluphenazine Hydrochloride Tablets, USP

Guanfacine Hydrochloride Extended-Release Tablets

Hydroquinone Cream

MegestrolAcetate Oral Suspension

Metformin Hydrochloride Extended Release Tablets

Metoprolol Succinate Extended-Release Tablets

Mycophenolic Acid DR Tablets

Nifedipine Extended-Release tablets

Paclitaxel Protein-Bound Particles for Injectable Suspension - (Albumin-Bound)

Propafenone Hydrochloride Extended-Release Capsules, USP

Sevelamer Carbonate Tablets

Sorafenib Tablets, USP

Testosterone Gel, 1.62% CIII

Terbutaline Sulfate tablets

Testosterone Topical Solution CIII, USP

Home > Products > For the United States

Sevelamer Carbonate Tablets

Route
Oral
Dosage form
Tablets
Strength
800mg
Rx/OTC
Rx
Indication
Lower the amount of phospherous in patients receiving kidney dialysis.
TE Rating
AB
Reference Listed Drug
Renvela®
ANDA#
200959
Strength Form Product Description Imprint Image How Supplied NDC Number HDMA
Sheets
PI SDS
800mg Tablets Off white, modified oval tablet core, imprinted “T186” on one side and plain on the reverse side, film coated white T186 Bottle of 270 24979-186-46

BackTop

©Copyright 2016 TWi Pharmaceuticals USA, Inc. All rights reserved.